News

10/03/2026 in Company News, Homepage News, Industry News, News Highlight

Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy

First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate…
Read More
09/15/2026 in Company News, Homepage News, Industry News, News Highlight

Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society

Late-Breaking selection at the 31st Annual World Muscle Society Congress — a designation reserved for…
Read More
08/06/2026 in Company News, Homepage News, Industry News, News Highlight, RAG-17, RAG-17 Presentation, Uncategorized

Ractigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS

Nantong, China, August 6, 2026 – Ractigen Therapeutics, a clinical-stage biotechnology company pioneering next-generation RNA…
Read More
07/31/2026 in Company News, Homepage News, Industry News, News Highlight, Uncategorized

Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy

RAG-1C achieves dual IND clearances from both U.S. FDA and China CDE, paving the way…
Read More